韦德布什分析师Laura Chico下调$Alto Neuroscience(ANRO.US)$至持有评级,并将目标价从29美元下调至4美元。根据TipRanks数据显示,该分析师近一年总胜率为44.4%,总平均回报率为3.1%。提示: TipRanks为独立第三方,提供金融分析师的分析数据,并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议,仅供参考。本文不...
ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024 Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday More Articles Select Price, Percent change, or Dollar change as the y-axis. Price Select Area, Line, OHLC or Candlestick as the chart type. ...
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) has announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of US$16 per share. The aggregate gross proceeds to Alto from the offering are expected to be approximately US$128.6...
We leverage the biology of individuals’ brains to develop personalized and highly effective medicines, helping patients get better faster.
Alto Neuroscience and Fractyl Health provided further momentum to the recent spate of biotech initial public offerings, with both companies going public on Friday morning in respective $128 million and $110 million IPOs.
Faring best this past week wasAlto Neuroscience (ANRO), which grossed $128.64 million through its upsized IPO, in which it sold 8.04 million shares of common stock at a public offering price of $16 per share. That’s the high end of its pricing range of $14–$16, and 20% more share...
Alto Neuroscience and Fractyl Health provided further momentum to the recent spate of biotech initial public offerings, with both companies going public on Friday morning in respective $128 million and $110 million IPOs.